Beta-cell specific autoantibodies: Are they just an indicator of type 1 diabetes?

Georgia Fousteri, Elio Ippolito, Rizwan Ahmed, Abdel Rahim A. Hamad

Research output: Research - peer-reviewReview article

Abstract

Background: Autoantibodies (AAbs) against islet autoantigens (AAgs) are used for type 1 diabetes (T1D) diagnosis and prediction. Islet-specific AAbs usually appear early in life and may fluctuate in terms of number and titer sometimes for over 20 years before T1D develops. Whereas their predictive power is high for pediatric subjects with high genetic risk who rapidly progress to multiple AAb positivity, they are less reliable for children with low genetic risk, single AAb positivity and slow disease progression. Objective: It is unknown how AAbs develop and whether they are involved in T1D pathogenesis. So far an increase in AAb number seems to only indicate AAg spreading and progression towards clinical T1D. The goal of this review is to shed light on the possible involvement of AAbs in T1D development. Method: We thoroughly review the current literature and discuss possible mechanisms of AAb development and the roles they may play in disease pathogenesis. Results: Genetic and environmental factors instigate changes at the molecular and cellular levels that promote AAb development. Although direct involvement of AAbs in T1D is less clear, autoreactive B cells are clearly involved in various immune and autoimmune responses via antigen presentation, immunoregulation and cytokine production. Conclusion: Our analysis suggests that understanding the mechanisms that lead to islet-specific AAb development and the diabetogenic processes that autoreactive B cells promote may uncover additional biomarkers and therapeutic targets.

LanguageEnglish (US)
Pages322-329
Number of pages8
JournalCurrent Diabetes Reviews
Volume13
Issue number3
DOIs
StatePublished - 2017

Fingerprint

Type 1 Diabetes Mellitus
Autoantibodies
B-Lymphocytes
Autoantigens
Antigen Presentation
Autoimmunity
Disease Progression
Biomarkers
Pediatrics
Cytokines
Therapeutics

Keywords

  • Autoantibodies
  • Biomarker
  • Diabetogenesis
  • Prediction
  • Prevention
  • Type 1 diabetes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Beta-cell specific autoantibodies : Are they just an indicator of type 1 diabetes? / Fousteri, Georgia; Ippolito, Elio; Ahmed, Rizwan; Hamad, Abdel Rahim A.

In: Current Diabetes Reviews, Vol. 13, No. 3, 2017, p. 322-329.

Research output: Research - peer-reviewReview article

Fousteri, Georgia ; Ippolito, Elio ; Ahmed, Rizwan ; Hamad, Abdel Rahim A./ Beta-cell specific autoantibodies : Are they just an indicator of type 1 diabetes?. In: Current Diabetes Reviews. 2017 ; Vol. 13, No. 3. pp. 322-329
@article{c228ae9879764e2f90b2c8d870c86b64,
title = "Beta-cell specific autoantibodies: Are they just an indicator of type 1 diabetes?",
abstract = "Background: Autoantibodies (AAbs) against islet autoantigens (AAgs) are used for type 1 diabetes (T1D) diagnosis and prediction. Islet-specific AAbs usually appear early in life and may fluctuate in terms of number and titer sometimes for over 20 years before T1D develops. Whereas their predictive power is high for pediatric subjects with high genetic risk who rapidly progress to multiple AAb positivity, they are less reliable for children with low genetic risk, single AAb positivity and slow disease progression. Objective: It is unknown how AAbs develop and whether they are involved in T1D pathogenesis. So far an increase in AAb number seems to only indicate AAg spreading and progression towards clinical T1D. The goal of this review is to shed light on the possible involvement of AAbs in T1D development. Method: We thoroughly review the current literature and discuss possible mechanisms of AAb development and the roles they may play in disease pathogenesis. Results: Genetic and environmental factors instigate changes at the molecular and cellular levels that promote AAb development. Although direct involvement of AAbs in T1D is less clear, autoreactive B cells are clearly involved in various immune and autoimmune responses via antigen presentation, immunoregulation and cytokine production. Conclusion: Our analysis suggests that understanding the mechanisms that lead to islet-specific AAb development and the diabetogenic processes that autoreactive B cells promote may uncover additional biomarkers and therapeutic targets.",
keywords = "Autoantibodies, Biomarker, Diabetogenesis, Prediction, Prevention, Type 1 diabetes",
author = "Georgia Fousteri and Elio Ippolito and Rizwan Ahmed and Hamad, {Abdel Rahim A.}",
year = "2017",
doi = "10.2174/1573399812666160427104157",
volume = "13",
pages = "322--329",
journal = "Current Diabetes Reviews",
issn = "1573-3998",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Beta-cell specific autoantibodies

T2 - Current Diabetes Reviews

AU - Fousteri,Georgia

AU - Ippolito,Elio

AU - Ahmed,Rizwan

AU - Hamad,Abdel Rahim A.

PY - 2017

Y1 - 2017

N2 - Background: Autoantibodies (AAbs) against islet autoantigens (AAgs) are used for type 1 diabetes (T1D) diagnosis and prediction. Islet-specific AAbs usually appear early in life and may fluctuate in terms of number and titer sometimes for over 20 years before T1D develops. Whereas their predictive power is high for pediatric subjects with high genetic risk who rapidly progress to multiple AAb positivity, they are less reliable for children with low genetic risk, single AAb positivity and slow disease progression. Objective: It is unknown how AAbs develop and whether they are involved in T1D pathogenesis. So far an increase in AAb number seems to only indicate AAg spreading and progression towards clinical T1D. The goal of this review is to shed light on the possible involvement of AAbs in T1D development. Method: We thoroughly review the current literature and discuss possible mechanisms of AAb development and the roles they may play in disease pathogenesis. Results: Genetic and environmental factors instigate changes at the molecular and cellular levels that promote AAb development. Although direct involvement of AAbs in T1D is less clear, autoreactive B cells are clearly involved in various immune and autoimmune responses via antigen presentation, immunoregulation and cytokine production. Conclusion: Our analysis suggests that understanding the mechanisms that lead to islet-specific AAb development and the diabetogenic processes that autoreactive B cells promote may uncover additional biomarkers and therapeutic targets.

AB - Background: Autoantibodies (AAbs) against islet autoantigens (AAgs) are used for type 1 diabetes (T1D) diagnosis and prediction. Islet-specific AAbs usually appear early in life and may fluctuate in terms of number and titer sometimes for over 20 years before T1D develops. Whereas their predictive power is high for pediatric subjects with high genetic risk who rapidly progress to multiple AAb positivity, they are less reliable for children with low genetic risk, single AAb positivity and slow disease progression. Objective: It is unknown how AAbs develop and whether they are involved in T1D pathogenesis. So far an increase in AAb number seems to only indicate AAg spreading and progression towards clinical T1D. The goal of this review is to shed light on the possible involvement of AAbs in T1D development. Method: We thoroughly review the current literature and discuss possible mechanisms of AAb development and the roles they may play in disease pathogenesis. Results: Genetic and environmental factors instigate changes at the molecular and cellular levels that promote AAb development. Although direct involvement of AAbs in T1D is less clear, autoreactive B cells are clearly involved in various immune and autoimmune responses via antigen presentation, immunoregulation and cytokine production. Conclusion: Our analysis suggests that understanding the mechanisms that lead to islet-specific AAb development and the diabetogenic processes that autoreactive B cells promote may uncover additional biomarkers and therapeutic targets.

KW - Autoantibodies

KW - Biomarker

KW - Diabetogenesis

KW - Prediction

KW - Prevention

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85021073985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021073985&partnerID=8YFLogxK

U2 - 10.2174/1573399812666160427104157

DO - 10.2174/1573399812666160427104157

M3 - Review article

VL - 13

SP - 322

EP - 329

JO - Current Diabetes Reviews

JF - Current Diabetes Reviews

SN - 1573-3998

IS - 3

ER -